Medtronic, which has been the focus of recent reports detailing its payments to doctors, is defending that practice. The Minneapolis Star Tribune reports: “At the annual shareholder meeting of Medtronic Inc.
Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
|
31
Aug |
Medtronic Defends Payments To PhysiciansCategory: Primary Care / General Practice | Leave a Comment |
Medtronic, which has been the focus of recent reports detailing its payments to doctors, is defending that practice. The Minneapolis Star Tribune reports: “At the annual shareholder meeting of Medtronic Inc.
|
31
Aug |
E-18 Corp. Completes International Patent Filing For Revolutionary “Self-Sheathing” Medical SyringesCategory: Medical Devices / Diagnostics | Leave a Comment |
E-18 Corp. (OTCBB:ETEN) announced that its wholly owned subsidiary SquareOne Medical, Inc., doing business as Protectus Medical Devices (”Protectus Medical Devices”), completed an international patent filing for its revolutionary self-sheathing medical safety syringe technology, opening substantial opportunities abroad.
|
31
Aug |
Urine LAM-ELISA Poor At Diagnosing TBCategory: Tuberculosis | Leave a Comment |
Urine LAM-ELISA does not appear to be useful as an independent diagnostic test for pulmonary tuberculosis (TB). A trial of the new diagnostic, described in the open access journal BMC Infectious Diseases found that it was only capable of identifying 50.7% of TB cases.
|
31
Aug |
Laser Breakthrough Opens Door To DNA ManipulationCategory: Medical Devices / Diagnostics | Leave a Comment |
Heralded as a breakthrough in laser technology that will benefit biomedicine by opening the door to DNA manipulation and other applications, scientists in the US have made the world’s smallest semiconductor laser that can focus light in a space smaller than a single protein molecule.
|
31
Aug |
Marketing Application For Vernakalant Intravenous (IV) Filed In Europe For The Treatment Of Atrial FibrillationCategory: Cardiovascular / Cardiology | Leave a Comment |
Merck & Co., Inc., Whitehouse Station, NJ, USA, which operates in many countries as Merck Sharp & Dohme Limited, announced today that the European Medicines Agency (EMEA) accepted for review the Company’s Marketing Authorisation Application (MAA) for regulatory approval of vernakalant intravenous (IV). The proposed indication for vernakalant IV is for the treatment of acute atrial fibrillation, which is the most common cardiac arrhythmia (abnormal heart rhythm).
|
30
Aug |
Dabigatran versus Warfarin in Patients with Atrial FibrillationCategory: Medic | Leave a Comment |
Background Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin …
|
30
Aug |
Can We Rely on RE-LY?Category: Medic | Leave a Comment |
(No abstract is available for this citation)
|
30
Aug |
Ticagrelor — Is There Need for a New Player in the Antiplatelet-Therapy Field?Category: Medic | Leave a Comment |
(No abstract is available for this citation)
|
30
Aug |
Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesCategory: Medic | Leave a Comment |
Background Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel.
Methods In this …
|
30
Aug |
Xhale Awarded NIH / NIMH SBIR (Small Business Innovation Research) Phase II Grant For A Breath-Based Medication Adherence SystemCategory: HIV / AIDS | Leave a Comment |
Xhale, Inc. has been awarded a $1.7 million Small Business Innovation Research (SBIR) Phase II grant by the NIH National Institute of Mental Health (NIMH) to continue the development of SMART (Self Monitoring and Reporting Therapeutics), a breath-based medication adherence system for HIV/AIDS therapies. In 2007, NIH / NIMH awarded Xhale an SBIR Phase I grant to test the technical merit of SMART.